Efficacy and Safety of Insulin Detemir

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

In the treatment of patients with diabetes, the tear of hypoglycemia is a major barrier to initiating, maintaining, and/or intensifying insulin therapy. Insulin detemir (Levemir® [Novo Nordisk A/S, Bagsvaerd, Denmark]) is a novel, long-acting, basal insulin analog associated with a reduced risk of hypoglycemia that is available to improve glycemic control. This article discusses clinical trial data on the safety and efficacy of insulin detemir in patients with type 1 and type 2 diabetes. In additions, results from the German cohort of the Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation (PREDICTIVETM) study, a large, multinational observational study examining the clinical effectiveness and safety of insulin detemir, are reviewed. Finally, an evaluation of these data serves to show how the highly predictable action of insulin detemir translates into effective glycemic control with a lower incidence of hypoglycemia.

Original languageEnglish (US)
Pages (from-to)21-32
Number of pages12
JournalEndocrinology and Metabolism Clinics of North America
Volume36
Issue numberSUPPL. 1
DOIs
StatePublished - Aug 2007

Fingerprint

Safety
Medical problems
Hypoglycemia
Long-Acting Insulin
Insulin
Denmark
Tears
Type 1 Diabetes Mellitus
Type 2 Diabetes Mellitus
Observational Studies
Insulin Detemir
Clinical Trials
Incidence
Therapeutics

ASJC Scopus subject areas

  • Endocrinology
  • Biochemistry

Cite this

Efficacy and Safety of Insulin Detemir. / Raskin, Philip.

In: Endocrinology and Metabolism Clinics of North America, Vol. 36, No. SUPPL. 1, 08.2007, p. 21-32.

Research output: Contribution to journalArticle

@article{13c90b25875d4fc78fe7f1dda62ea9d7,
title = "Efficacy and Safety of Insulin Detemir",
abstract = "In the treatment of patients with diabetes, the tear of hypoglycemia is a major barrier to initiating, maintaining, and/or intensifying insulin therapy. Insulin detemir (Levemir{\circledR} [Novo Nordisk A/S, Bagsvaerd, Denmark]) is a novel, long-acting, basal insulin analog associated with a reduced risk of hypoglycemia that is available to improve glycemic control. This article discusses clinical trial data on the safety and efficacy of insulin detemir in patients with type 1 and type 2 diabetes. In additions, results from the German cohort of the Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation (PREDICTIVETM) study, a large, multinational observational study examining the clinical effectiveness and safety of insulin detemir, are reviewed. Finally, an evaluation of these data serves to show how the highly predictable action of insulin detemir translates into effective glycemic control with a lower incidence of hypoglycemia.",
author = "Philip Raskin",
year = "2007",
month = "8",
doi = "10.1016/S0889-8529(07)80005-3",
language = "English (US)",
volume = "36",
pages = "21--32",
journal = "Endocrinology and Metabolism Clinics of North America",
issn = "0889-8529",
publisher = "W.B. Saunders Ltd",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Efficacy and Safety of Insulin Detemir

AU - Raskin, Philip

PY - 2007/8

Y1 - 2007/8

N2 - In the treatment of patients with diabetes, the tear of hypoglycemia is a major barrier to initiating, maintaining, and/or intensifying insulin therapy. Insulin detemir (Levemir® [Novo Nordisk A/S, Bagsvaerd, Denmark]) is a novel, long-acting, basal insulin analog associated with a reduced risk of hypoglycemia that is available to improve glycemic control. This article discusses clinical trial data on the safety and efficacy of insulin detemir in patients with type 1 and type 2 diabetes. In additions, results from the German cohort of the Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation (PREDICTIVETM) study, a large, multinational observational study examining the clinical effectiveness and safety of insulin detemir, are reviewed. Finally, an evaluation of these data serves to show how the highly predictable action of insulin detemir translates into effective glycemic control with a lower incidence of hypoglycemia.

AB - In the treatment of patients with diabetes, the tear of hypoglycemia is a major barrier to initiating, maintaining, and/or intensifying insulin therapy. Insulin detemir (Levemir® [Novo Nordisk A/S, Bagsvaerd, Denmark]) is a novel, long-acting, basal insulin analog associated with a reduced risk of hypoglycemia that is available to improve glycemic control. This article discusses clinical trial data on the safety and efficacy of insulin detemir in patients with type 1 and type 2 diabetes. In additions, results from the German cohort of the Predictable Results and Experience in Diabetes through Intensification and Control to Target: An International Variability Evaluation (PREDICTIVETM) study, a large, multinational observational study examining the clinical effectiveness and safety of insulin detemir, are reviewed. Finally, an evaluation of these data serves to show how the highly predictable action of insulin detemir translates into effective glycemic control with a lower incidence of hypoglycemia.

UR - http://www.scopus.com/inward/record.url?scp=34548594034&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548594034&partnerID=8YFLogxK

U2 - 10.1016/S0889-8529(07)80005-3

DO - 10.1016/S0889-8529(07)80005-3

M3 - Article

C2 - 17881329

AN - SCOPUS:34548594034

VL - 36

SP - 21

EP - 32

JO - Endocrinology and Metabolism Clinics of North America

JF - Endocrinology and Metabolism Clinics of North America

SN - 0889-8529

IS - SUPPL. 1

ER -